Medtronic USA Inc.

Medtronic USA Inc. manufactures and supplies surgical implants, prosthetic devices, cardiovascular intervention equipment, and surgical navigation systems to the federal government as a prime contractor across full-and-open procurements with no small business set-asides. The company is a foreign-owned, for-profit medical device manufacturer headquartered in Minneapolis, Minnesota, competing predominantly on unrestricted competitive procurements rather than under any set-aside category.

Medtronic's federal footprint centers on medical device procurement across two primary capability areas. Surgical implant supply dominates the portfolio: pacemakers, prosthetic implants (spinal fusion components, deep brain stimulation devices), cardiac mapping and ablation systems, and neurostimulators. Cardiovascular procedural equipment comprises the second major category—diagnostic and guide catheters, drug-coated balloons, stents, ablation catheters, and related consumables. A smaller portfolio includes surgical navigation system maintenance and on-site preventive maintenance for specialized surgical equipment such as the StealthStation S8 Surgical Navigation System with Fusion ENT Navigation System and O-Arm O2 Imaging System. Recent representative work includes a $6.685 million VA Medical Center cardiac mapping ablation system acquisition (June 2026), a $247.980 million three-year maintenance contract with VA Nashville for surgical navigation system full-service support through July 2029, and recurring Defense Logistics Agency Medical Supply Chain delivery orders for pacemaker leads, stents, catheters, and neuromodulation devices at values ranging from several hundred dollars to $170.340 million per order.

Customer concentration is steep and heavily tilted toward the Defense Logistics Agency and the Department of Veterans Affairs. The Defense Logistics Agency Medical Supply Chain accounts for 2,373 awards worth $138.9 million combined potential value, representing approximately 19% of Medtronic's federal portfolio by count and 12% by dollars. The VA Veterans Health Administration disperses awards across regional Veterans Integrated Service Networks (VISNs); the top five VISNs (10, 17, 7, 22, and 8) collectively hold 5,792 awards worth $188.8 million. Together, DLA Medical Supply Chain and the top five VA VISNs account for roughly 46% of Medtronic's recent award count and 26% of combined potential value. The fragmentation across multiple VA networks and DLA supply channels creates a decentralized customer base, but DoD-affiliated buyers (DLA and Defense Health Agency) and VA health systems account for the vast majority of invoiced federal spend.

Medtronic's vehicle position is dominated by the legacy VA Prosthetic Implants and Appliances contract (2016–2021), which carries 9,198 task orders worth $220.9 million combined potential value and anchors roughly 58% of Medtronic's total federal award count. This vehicle is past its initial performance period but remains active in delivery order issuance. The company also holds position on an Indefinite Delivery Contract (SPE2DE23DA011) with 2,349 task orders worth $21 million, and several blanket purchase agreements including FA860116A0006 (41 task orders, $4.4 million) and HT001416A0070 (31 task orders, $6.6 million). The DLA Medical Supply Chain represents an open, recurring delivery-order environment rather than a single parent vehicle; Medtronic is a sole-source provider for integrated cardiovascular procedural packages to DoD hospitals and clinics nationwide under that arrangement. A single-award VISN 9 maintenance contract with a ceiling of $1.120 million (awarded July 2024, running through July 2029) supports the StealthStation maintenance work.

Activity has remained relatively steady with some compression in 2025–2026. Medtronic recorded 370 awards in 2022, growing to 1,075 in 2024, then declining to 951 in 2025 and 480 year-to-date through mid-October 2026. The company faces minimal recompete cliff exposure: only 35 awards (combined potential value $7.5 million) are scheduled for ultimate completion within the next twenty-four months. The massive base of nearly 10,000 task orders under the legacy VA Prosthetic Implants and Appliances vehicle and ongoing DLA delivery orders insulate Medtronic from sudden revenue loss, but the aging VA contract vehicle and the declining award velocity over the past two years suggest the portfolio is transitioning to routine sustainment and replenishment rather than major new platform adoption.

Medtronic operates as a 100% prime contractor across its federal footprint; the source reports only a single federal grant sub-award (a Washington University-led NIH project integrating resting-state functional MRI software with Medtronic StealthStation navigation systems, awarded July 2024). The company's federal strategy does not rely on subcontracting or strategic teaming; instead, it wins awards on the strength of sole-source device qualification (particularly for cardiovascular and neuromodulation products) and established relationships with VA health systems and DLA supply chain buyers.